<DOC>
	<DOCNO>NCT00199290</DOCNO>
	<brief_summary>This study design evaluate efficacy safety Trafermin ( recombinant human basic fibroblast growth factor : rhbFGF ) Japanese patient marginal periodontitis , order verify superiority Trafermin placebo , determine recommend therapeutic dose .</brief_summary>
	<brief_title>A Phase2 Clinical Trial Trafermin Patients With Marginal Periodontitis Japan</brief_title>
	<detailed_description />
	<mesh_term>Periodontitis</mesh_term>
	<criteria>The patient marginal periodontitis intend conduct flap operation ( modified Widman ) must meet following criterion : Alveolar bone defect diagnose radiography . Mobility teeth must &lt; =2 width attach gingiva suitable GTR ( guide tissue regeneration ) method . Males female , &gt; =20 year age . Patients exclude study follow condition present : Concomitant administration adrenal cortical steroid within 4weeks treatment trial . Current previous history gingival overgrowth drug . Current previous history cancer malignant tumour . Presence diabetes mellitus ( HbA1c &gt; =6.5 % ) Presence malnutrition ( serum albumin &lt; =2g/dL ) Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Trafermin</keyword>
	<keyword>Periodontitis</keyword>
</DOC>